HSD17B13 and metabolic dysfunction-associated steatohepatitis: Asthe in vivo pharmacokinetic/pharmacodynamic (PK/PD)relationship of BI-3231 including target engagement biomarkersfor HSD17B13 inhibition are not known, further in vivo evaluation in relevant models of NASH is required.